Harm Reduction

March 16, 2025 | Controlled Substances, Drug Courts, Fact Sheets, Harm Reduction, Peer Support and Recoery Services, Public Health, Public Safety, Recovery, Treatments

In 2014, several U.S. cities and counties filed lawsuits against drug manufacturers and distributors alleging that the companies’ aggressive marketing practices fueled a national opioid addiction epidemic that subsequently killed hundreds of thousands of people. Since then, over 3,000 state and local governments filed lawsuits of their own, seeking to recoup the billions of dollars that these entities spent—and continue to spend—on the fallout from the epidemic. The result of these legal efforts is a series of ongoing monetary settlements, greater than $56 billion to date. Payment of these settlements will last 18 years, and the decision-making authority for spending these funds differs between jurisdictions. Many have an appointed advisory board that disburses specified amounts each year for specified purposes. In this fact sheet, LAPPA details how opioid settlement proceeds are being disbursed to state and local governments, how those governments are choosing to spend those funds, and the obstacles that can prevent these funds from helping those who have been affected by the opioid epidemic....

March 5, 2025 | Controlled Substances, Fact Sheets, Fentanyl, Harm Reduction, Public Safety, Synthetic Drugs

In mid 2024, community-based drug checking programs discovered the industrial chemical bis (2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS) in the illicit opioid supply in Portland, Oregon and Philadelphia, Pennsylvania. The substance appears as a white powder, and on industrial chemical websites, it is often referred to by its brand name, Tinuvin® 770. Used, among other things, as a protective coating on plastics to provide protection against ultraviolet rays, BTMPS belongs to a class of molecules called hindered amine light stabilizers. It is not approved for use in humans or animals, and it is not a scheduled or regulated substance in the U.S. This fact sheet provides an overview of the sudden increase in the presence of BTMPS in the illicit drug supply and its rapid proliferation across the country, which has left drug policy experts and harm reduction specialists puzzled as to why it is in the supply and how it will affect the individuals consuming it....

October 24, 2024 | Emergency Departments, Harm Reduction, Innovative Initiatives, Medication Assisted Treatment (MAT), Public Health, Recovery, Substance Misuse, Treatments

To complement the opioid prescribing guidelines that the University of Buffalo Department of Emergency Medicine established in 2016, Dr. Joshua Lynch developed the Medication for Addiction Treatment and Electronic Referrals (MATTERS) program. He saw the need for MATTERs because the “window of opportunity” to help someone with a substance use disorder is small, and he wanted to immediately link a patient who had overdosed to a treatment program that is right for that individual....

October 17, 2024 | First Responders, Harm Reduction, Model Laws, Naloxone, Opioid Antagonists, Opioid Antagonists, Recovery, Substance Misuse, Treatments

The key elements of the Model Overdose Reversal Agents Act are to: (1) remove all existing restrictions about who can receive, possess, store, transfer without cost, or administer an ORA such that any “person or entity” is eligible; (2) require specified individuals and entities to offer ORAs to individuals at increased risk of overdose; (3) require emergency access to ORAs at specified locations for use by any individual; (4) provide guidelines for ORA sales, in particular sales of non-prescription ORAs; (6) grant broad immunity to people or entities for prescribing, dispensing, giving, donating, transferring without charge, selling, or administering ORAs in the absence of gross negligence, malice, or criminal intent; (7) identify the required content for educational information about ORAs and specify when that information must be disseminated; (8) require Medicaid and other health insurance coverage for ORAs, including non-prescription ORAs, and prohibit discriminatory life and health insurance practices; and (9) create a bulk overdose reversal agent purchasing fund to assist persons and entities to fulfill requirements under the Act....

October 2, 2024 | Harm Reduction, Innovative Initiatives, Naloxone, Opioid Antagonists, Opioid Antagonists, Recovery, Substance Misuse

In 2018, the city of Chicago, IL gained an ally in the fight against fatal overdoses and substance use disorder in the non-profit organization, To Walk in My Shoes. Co-founded by Marnell Brown, a person in long term recovery, To Walk in My Shoes provides resources and support for those in need in the community. In addition to providing individuals with job skills training, including interview practice and how to write a resume, money management skills, and conflict resolution skills, To Walk in My Shoes also works to raise awareness about and provide testing for HIV/AIDS....

May 12, 2024 | Emergency Departments, First Responders, Harm Reduction, Innovative Initiatives, Medication Assisted Treatment (MAT), Opioid Antagonists, Opioid Antagonists, Opioids, Public Health, Recovery, Substance Misuse, Treatments

Paramedics in the State of New Jersey are permitted to carry and administer buprenorphine to treat acute withdrawal symptoms after having had an opioid overdose reversed with naloxone. The directive, via Executive Order from the State Health Commissioner, simply added buprenorphine to the list of medications available to paramedics in the MICUs and required officials in each county to train paramedics on the protocol. ...

April 11, 2024 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioid Antagonists, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Misuse, Treatments

The Addiction and Public Policy Initiative at the O’Neill Institute for National and Global Health Law was established in 2018 through a generous grant from Arnold Ventures. Housed at Georgetown Law, the Addiction and Public Policy Initiative works at the intersection of public health and the law to advance a public health approach to substance use disorder and the overdose epidemic through legal and policy strategies that promote evidence-based treatment, harm reduction, and recovery. This reports highlights O'Neill's accomplishments over the last five years....

January 16, 2024 | Controlled Substances, Harm Reduction, Reports & Studies, Stimulants, Substance Misuse, Treatments

Total abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. The researchers and authors of this report aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials of pharmacological interventions for stimulant use disorder....

September 11, 2023 | Harm Reduction, Innovative Initiatives, Peer Support and Recoery Services, Recovery, Reentry

Legendary Legacies, a Worcester, Massachusetts gang rehabilitation and reentry nonprofit organization, serves men of color aged 17-24 who are not served by traditional educational, legal, or community-based entities. Based on four pillars: (1) belief; (2) opportunity; (3) transformation; and (4) brotherhood, the faith-inspired program provides participants with the basic life skills, case management assistance, family support services, and recreational and service opportunities through mentorships. The goal is to reduce recidivism and for these individuals to ultimately become contributing members of the community. ...